Two cases with clinical signs ofpulmonary hypertension and right heart failure developing during phenformin treatment are reported. The patients were clinically improved on withdrawal of phenformin. Two possible explanations for the pulmonary hypertension were considered: cellular anaerobiosis or alphareceptor stimulation of the pulmonary vessels. The 4 patients so far reported direct attention to the possibility that pulmonary hypertension might appear as a side effect to treatment with biguanides. to deteriorate with increasing dyspnoea, tiredness, and then anorexia. A chest x-ray two months after being admitted (July) showed normal lung fields but increasing heart size (950/540 ml/m2 BSA). A complete picture of right ventricular hypertrophy and some right-sided intraventricular conduction defect had developed on the electrocardiogram. Orthopnoea and breathlessness while talking were noted from November I969 together with ankle oedema and peripheral cyanosis. He could hardly manage to walk more than 40 metres or up one flight of stairs before the onset of severe dyspnoea. There were pulsations at the left sternal border. The pulmonary component ofthe second heart sound was sufficiently pronounced to be palpable. A fourth heart sound was heard at the third and fourth intercostal space at the left sternal border. These findings were confirmed by phonocardiography in February 1970 (Fig. Ia) . The blood pressure was 140/70 mmHg. The electrocardiographic pattern was unchanged as compared to that of July I969 but an intermittent sinoatrial block and some premature beats of ventricular origin were added. A vectorcardiogram showed pronounced right ventricular hypertrophy (Fig. 2) . The heart size had increased to 12I0/680 ml/m2 BSA, while the lungs were normal. The vital capacity was decreased to 2-9 litres. FEVl.o was normal as was intrapulmonary gas mixing (single breath). At right-sided catheterization the pulmonary artery pressure was 72/I6:32 mmHg (Table) . There was no shunt. Blood gas estimation revealed slight alveolar hyperventilation. Pulmonary angiography, lung-scanning, and 133Xe studies of the pulmonary perfusion did not give any evidence of pulmonary embolism. Angiography of the leg, pelvic, and inferior caval veins did not show any signs of earlier or present thromboses. There were no signs of increased blood coagulability. Hepatic and renal function tests were normal.
Two cases with clinical signs ofpulmonary hypertension and right heart failure developing during phenformin treatment are reported. The patients were clinically improved on withdrawal of phenformin. Two possible explanations for the pulmonary hypertension were considered: cellular anaerobiosis or alphareceptor stimulation of the pulmonary vessels. The 4 patients so far reported direct attention to the possibility that pulmonary hypertension might appear as a side effect to treatment with biguanides.
There have been several reports of severe lactic acidosis in patients treated with biguanides and a relation has been inferred (Marble, I96I; Bernier, Miller, and Springate, I963; house, I968). In addition in 2 patients who were being treated with phenformin clinical signs of pulmonary hypertension were attributed to a concomitant raised blood lactate content (Sproule et al., I966; Duwoos et al., 1970) . Animal experiments have shown pulmonary vasoconstriction induced by the infusion of lactic acid into the pulmonary artery (Bergofsky, Lehr, and Fishman, I962) . Furthermore, it has been proposed that an intrapulmonary release of lactic acid causes the vascular constriction during hypoxia (Liljestrand, I958 to deteriorate with increasing dyspnoea, tiredness, and then anorexia. A chest x-ray two months after being admitted (July) showed normal lung fields but increasing heart size (950/540 ml/m2 BSA). A complete picture of right ventricular hypertrophy and some right-sided intraventricular conduction defect had developed on the electrocardiogram. Orthopnoea and breathlessness while talking were noted from November I969 together with ankle oedema and peripheral cyanosis. He could hardly manage to walk more than 40 metres or up one flight of stairs before the onset of severe dyspnoea. There were pulsations at the left sternal border. The pulmonary component ofthe second heart sound was sufficiently pronounced to be palpable. A fourth heart sound was heard at the third and fourth intercostal space at the left sternal border. These findings were confirmed by phonocardiography in February 1970 (Fig. Ia) . The blood pressure was 140/70 mmHg. The electrocardiographic pattern was unchanged as compared to that of July I969 but an intermittent sinoatrial block and some premature beats of ventricular origin were added. A vectorcardiogram showed pronounced right ventricular hypertrophy (Fig. 2) . The heart size had increased to 12I0/680 ml/m2 BSA, while the lungs were normal. The vital capacity was decreased to 2-9 litres. FEVl.o was normal as was intrapulmonary gas mixing (single breath). At right-sided catheterization the pulmonary artery pressure was 72/I6:32 mmHg (Table) . There was no shunt. Blood gas estimation revealed slight alveolar hyperventilation. Pulmonary angiography, lung-scanning, and 133Xe studies of the pulmonary perfusion did not give any evidence of pulmonary embolism. Angiography of the leg, pelvic, and inferior caval veins did not show any signs of earlier or present thromboses. There were no signs of increased blood coagulability. Hepatic and renal function tests were normal.
At the end of February I970 phenformin was stopped. Thereafter the patient was treated with a sulphonylurea and a diuretic was administered intermittently. Gradual relief of symptoms ensued and one month after with-Phenformin and pulmonary hypertension 82z drawal of the drug the patient was able to walk about two kilometres and managed 400 kpm/hour on a bicycle ergometer.
During October to November I970 the patient managed to walk about 9 kilometres. There were then no signs of cyanosis, oedema, or parasternal pulsations. Only a very slight accentuation of the pulmonary component of the second heart sound and no fourth heart sound could be heard (Fig. ib) ; blood pressure i60/90 mmHg. A slight intraventricular conduction defect was still present on the electrocardiogram and vectorcardiogram but there were no signs of right ventricular hypertrophy or strain (Fig. 2) . Chest x-ray revealed a decrease in heart size (920/540 ml per m2 BSA). Vital capacity was normal (4-I 1.) as well as FEV1.0 (3-2 1.).
Blood gases were normal. Right-sided catheterization was performed (floating technique) and pulmonary artery pressure was 38/Ii :22 mmHg (Table) .
Subsequently the patient did well until December I971 when increasing orthopnoea and breathlessness were noted. The patient was admitted to the local hospital with severe systemic hypertension and died suddenly.
At necropsy, evidence of pulmonary hypertension and sarcoidosis was found. Pulmonary oedema, hydrothorax, and signs of stasis in the liver and the spleen were present. The heart (589 g) was enlarged. The group.bmj.com on October 22, 2017 -Published by http://heart.bmj.com/ Downloaded from signs of pulmonary hypertension. There was rightsided heart failure with hepatomegaly and oedema of the lower limbs. Concomitantly there was hyperlactataemia and muscle weakness. The clinical and laboratory signs of toxicity regressed on stopping phenformin. In our cases similar clinical pictures were observed with evidence of pulmonary hypertension and right heart failure during treatment with phenformin, and improvement gradually occurring after withdrawal of phenformin. In both cases the situation was confirmed by laboratory investigations.
Pulmonary embolism was a presumptive diagnosis in both cases but no signs of thrombi or pulmonary emboli could be demonstrated. The proliferative changes found in the lung vessels in Case i were consistent with primary pulmonary hypertension but were otherwise nonspecific (Wagenvoort and Wagenvoort, I970) .
At necropsy the finding of sarcoidosis in Case i was surprising. It is known that sarcoidosis in the lungs, if it is severe with signs of fibrosis, can cause pulmonary hypertension (Svanborg, I96I). The patient, however, had no radiological signs of pulmonary sarcoidosis and it is unlikely that the rapid and pronounced improvement seen in this case fits the natural course of sarcoidosis. Furthermore, sarcoidosis was not considered likely as a cause for the pulmonary hypertension as there was improvement when the drug was withdrawn.
In discussing the role of phenformin in pulmonary hypertension account must first be taken of the fact that there is a great difference in pulmonary vascular reactivity between individuals and that many aetiological factors in pulmonary hypertension are still obscure (Hurst and Logue, I970) .
Several reports have suggested that appetitedepressing drugs, such as aminorex, induce pulmonary hypertension (Gurtner et al., I968; Gurtner, I969; Lang et al., i969 (Liljestrand, 1958; Bergofsky et al., 
I962).
The present observations and the earlier cases reported (Sproule et al., i966; Duwoos et al., 1970) indicate the need for watchfulness for the development of pulmonary hypertension in patients taking biguanides.
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